BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-33. [PMID: 22237311 DOI: 10.1038/npp.2011.310] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
2 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, Mcdonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5:179ra44. [PMID: 23552372 DOI: 10.1126/scitranslmed.3005213] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
4 Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci 2014;8:28. [PMID: 24592208 DOI: 10.3389/fnins.2014.00028] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
5 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
7 Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends Neurosci 2016;39:552-66. [PMID: 27325209 DOI: 10.1016/j.tins.2016.05.002] [Cited by in Crossref: 201] [Cited by in F6Publishing: 179] [Article Influence: 33.5] [Reference Citation Analysis]
8 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
9 Roth T, Black J, Cluydts R, Charef P, Cavallaro M, Kramer F, Zammit G, Walsh J. Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study. Sleep 2017;40. [PMID: 28364509 DOI: 10.1093/sleep/zsw034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
10 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
11 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
12 Rivas M, Serantes D, Peña F, González J, Ferreira A, Torterolo P, Benedetto L. Role of Hypocretin in the Medial Preoptic Area in the Regulation of Sleep, Maternal Behavior and Body Temperature of Lactating Rats. Neuroscience 2021;475:148-62. [PMID: 34500018 DOI: 10.1016/j.neuroscience.2021.08.034] [Reference Citation Analysis]
13 O'Callaghan EK, Green EW, Franken P, Mongrain V. Omics Approaches in Sleep-Wake Regulation. Handb Exp Pharmacol 2019;253:59-81. [PMID: 29796779 DOI: 10.1007/164_2018_125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
14 Revell VL, Della Monica C, Mendis J, Hassanin H, Halter RJ, Chaplan SR, Dijk DJ. Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial. Neuropsychopharmacology 2021. [PMID: 34628482 DOI: 10.1038/s41386-021-01175-3] [Reference Citation Analysis]
15 Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 2013;7:254. [PMID: 24399926 DOI: 10.3389/fnins.2013.00254] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
16 Sullivan S. Update on emerging drugs for insomnia. Expert Opinion on Emerging Drugs 2012;17:295-8. [DOI: 10.1517/14728214.2012.693158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
17 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Stasi LP, Artusi R, Bovino C, Buzzi B, Canciani L, Caselli G, Colace F, Garofalo P, Giambuzzi S, Larger P, Letari O, Mandelli S, Perugini L, Pucci S, Salvi M, Toro P. Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists. Bioorg Med Chem Lett 2013;23:2653-8. [PMID: 23535328 DOI: 10.1016/j.bmcl.2013.02.093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
19 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
20 Struyk A, Gargano C, Drexel M, Stoch SA, Svetnik V, Ma J, Mayleben D. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. Eur Neuropsychopharmacol 2016;26:1649-56. [PMID: 27554636 DOI: 10.1016/j.euroneuro.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
21 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
22 Jarrahi M, Sedighi Moghadam B, Torkmandi H. An experimental evaluation of a new designed apparatus (NDA) for the rapid measurement of impaired motor function in rats. J Neurosci Methods 2015;251:138-42. [PMID: 26051554 DOI: 10.1016/j.jneumeth.2015.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
23 Kuduk SD, Winrow CJ, Coleman PJ. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. Elsevier; 2013. pp. 73-87. [DOI: 10.1016/b978-0-12-417150-3.00006-5] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bai P, Bai S, Placzek MS, Lu X, Fiedler SA, Ntaganda B, Wey HY, Wang C. A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging. Molecules 2020;25:E1018. [PMID: 32106419 DOI: 10.3390/molecules25051018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
25 Xiang T, Cai Y, Hong Z, Pan J. Efficacy and safety of Zolpidem in the treatment of insomnia disorder for one month: a meta-analysis of a randomized controlled trial. Sleep Med 2021;87:250-6. [PMID: 34688027 DOI: 10.1016/j.sleep.2021.09.005] [Reference Citation Analysis]
26 Hoyer D, Dürst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci 2013;7:235. [PMID: 24368893 DOI: 10.3389/fnins.2013.00235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
27 Abad VC, Guilleminault C. Pharmacological treatment of sleep disorders and its relationship with neuroplasticity. Curr Top Behav Neurosci 2015;25:503-53. [PMID: 25585962 DOI: 10.1007/7854_2014_365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Sauter C, Kowalski JT, Stein M, Röttger S, Danker-Hopfe H. Effects of a Workplace-Based Sleep Health Program on Sleep in Members of the German Armed Forces. J Clin Sleep Med 2019;15:417-29. [PMID: 30853042 DOI: 10.5664/jcsm.7666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19. [PMID: 25197807 DOI: 10.5665/sleep.4068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
30 Uslaner JM, Renger JJ, Coleman PJ, Winrow CJ. A New Class of Hypnotic Compounds for the Treatment of Insomnia: The Dual Orexin Receptor Antagonists. In: Sakurai T, Pandi-perumal S, Monti JM, editors. Orexin and Sleep. Cham: Springer International Publishing; 2015. pp. 323-38. [DOI: 10.1007/978-3-319-23078-8_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep 2016;39:603-12. [PMID: 26943466 DOI: 10.5665/sleep.5536] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
32 Arbon EL, Knurowska M, Dijk D. Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people. J Psychopharmacol 2015;29:764-76. [DOI: 10.1177/0269881115581963] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
33 Suzuki R, Nozawa D, Futamura A, Nishikawa-shimono R, Abe M, Hattori N, Ohta H, Araki Y, Kambe D, Ohmichi M, Tokura S, Aoki T, Ohtake N, Kawamoto H. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist. Bioorganic & Medicinal Chemistry 2015;23:1260-75. [DOI: 10.1016/j.bmc.2015.01.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
34 Hamidovic A. Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation. CNS Drugs 2022. [PMID: 35451800 DOI: 10.1007/s40263-022-00918-0] [Reference Citation Analysis]
35 Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. Eur Neuropsychopharmacol 2013;23:107-17. [PMID: 22658401 DOI: 10.1016/j.euroneuro.2012.04.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
36 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]
37 Fitzgerald AC, Wright BT, Heldt SA. The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors. Psychopharmacology (Berl) 2014;231:1865-96. [PMID: 24563183 DOI: 10.1007/s00213-014-3457-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
38 Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;27:83-90. [PMID: 23359095 DOI: 10.1007/s40263-012-0036-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
39 Nesbitt AD, Leschziner GD, Peatfield RC. Headache, drugs and sleep. Cephalalgia 2014;34:756-66. [DOI: 10.1177/0333102414542662] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
40 Kumar S, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harassi A, Abdel-Daim MM, Bungau S. Exploring the Role of Orexinergic Neurons in Parkinson's Disease. Neurotox Res 2021. [PMID: 34495449 DOI: 10.1007/s12640-021-00411-4] [Reference Citation Analysis]
41 Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012;35:1097-104. [PMID: 22851805 DOI: 10.5665/sleep.1996] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
42 Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin Sleep Med 2021;17:1167-74. [PMID: 33590823 DOI: 10.5664/jcsm.9150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Shariq AS, Rosenblat JD, Alageel A, Mansur RB, Rong C, Ho RC, Ragguett R, Pan Z, Brietzke E, Mcintyre RS. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;92:1-7. [DOI: 10.1016/j.pnpbp.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
44 Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J Pharmacol Exp Ther 2017;362:489-503. [DOI: 10.1124/jpet.117.241596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
45 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
46 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Cerri M, Del Vecchio F, Mastrotto M, Luppi M, Martelli D, Perez E, Tupone D, Zamboni G, Amici R. Enhanced slow-wave EEG activity and thermoregulatory impairment following the inhibition of the lateral hypothalamus in the rat. PLoS One 2014;9:e112849. [PMID: 25398141 DOI: 10.1371/journal.pone.0112849] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
48 Wang C, Wilson CM, Moseley CK, Carlin SM, Hsu S, Arabasz G, Schroeder FA, Sander CY, Hooker JM. Evaluation of potential PET imaging probes for the orexin 2 receptors. Nucl Med Biol 2013;40:1000-5. [PMID: 23953751 DOI: 10.1016/j.nucmedbio.2013.07.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
49 Winsky-sommerer R, de Oliveira P, Loomis S, Wafford K, Dijk D, Gilmour G. Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: Insights from studies in patient populations and animal models. Neuroscience & Biobehavioral Reviews 2019;97:112-37. [DOI: 10.1016/j.neubiorev.2018.09.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
50 Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 2014;8:182. [PMID: 24904334 DOI: 10.3389/fnbeh.2014.00182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
51 Dijk DJ, Landolt HP. Sleep Physiology, Circadian Rhythms, Waking Performance and the Development of Sleep-Wake Therapeutics. Handb Exp Pharmacol 2019;253:441-81. [PMID: 31254050 DOI: 10.1007/164_2019_243] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
52 Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther 2017;362:287-95. [PMID: 28559480 DOI: 10.1124/jpet.117.241422] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
53 Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012;35:1625-35. [PMID: 23204605 DOI: 10.5665/sleep.2232] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
54 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
55 Clark JW, Brian ML, Drummond SP, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews 2020;53:101332. [DOI: 10.1016/j.smrv.2020.101332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
56 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
57 Patel AX, Miller SR, Nathan PJ, Kanakaraj P, Napolitano A, Lawrence P, Koch A, Bullmore ET. Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans. Psychopharmacology (Berl) 2014;231:3817-28. [PMID: 24770625 DOI: 10.1007/s00213-014-3520-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
58 Zhang Y, Su J, Wang J, Tang G, Hu W, Mao J, Ren W, Liu Y, Yu Z. Cognitive behavioral therapy for insomnia combined with eszopiclone for the treatment of sleep disorder patients transferred out of the intensive care unit: A single-centred retrospective observational study. Medicine (Baltimore) 2018;97:e12383. [PMID: 30213004 DOI: 10.1097/MD.0000000000012383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
59 Foltin RW, Evans SM. Hypocretin/orexin antagonists decrease cocaine self-administration by female rhesus monkeys. Drug Alcohol Depend 2018;188:318-27. [PMID: 29852449 DOI: 10.1016/j.drugalcdep.2018.04.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
60 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
61 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
62 Matsunaga Y, Tagaya H, Fukase Y, Hakamata Y, Murayama N, Kumagai Y, Kuroyama M. Effects of zolpidem/triazolam on cognitive performance 12 hours after acute administration. Sleep Med 2018;52:213-8. [PMID: 30097333 DOI: 10.1016/j.sleep.2018.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Pałasz A, Lapray D, Peyron C, Rojczyk-Gołębiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol 2014;17:157-68. [PMID: 23702225 DOI: 10.1017/S1461145713000552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
64 Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 2013;38:2401-8. [PMID: 23722242 DOI: 10.1038/npp.2013.139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]